1 / 33

ACTION A C oronary disease T rial I nvestigating O utcome with N ifedipine GITS (gastrointestinal therapeutic system

ACTION A C oronary disease T rial I nvestigating O utcome with N ifedipine GITS (gastrointestinal therapeutic system). presented by Philip A Poole-Wilson on behalf of the ACTION investigators. ACTION: rationale. Nifedipine GITS is widely used to treat angina and hypertension

niveditha
Download Presentation

ACTION A C oronary disease T rial I nvestigating O utcome with N ifedipine GITS (gastrointestinal therapeutic system

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ACTIONACoronary disease Trial Investigating Outcome with Nifedipine GITS(gastrointestinal therapeutic system) presented by Philip A Poole-Wilsonon behalf of the ACTION investigators

  2. ACTION: rationale • Nifedipine GITS is widely used to treat angina and hypertension • Debate circa 1995 on safety based on: • Data from unapproved indications • Observational studies • Meta-analyses (Furberg, 1995) • Short-acting formulations of nifedipine possibly harmful • No evidence from outcome trials in patients with stable angina

  3. ACTION: features • First-ever placebo-controlled clinical out-come trial in symptomatic stable angina • Long-acting nifedipine (GITS) • Investigator initiated and designed • Independent Steering Committee and study management (SOCAR Research) • Multi-centre (291 centres, 19 countries) • 7665 patients, mean f-up 4.9 years • Supported by Bayer HealthCare AG

  4. ACTION: primary objective Effect of: addition of 60 mg once-daily long-acting nifedipine GITS to the basic regimen ( blockers, nitrates, lipid lowering…) On: cardiovascular event-free survival In: patients with stable symptomatic coro-nary disease (angina pectoris)

  5. ACTION: primary endpoints For efficacy: combined rate of • Death (any cause) • MI (acute or procedural) • Refractory angina  angiography • New overt HF  hospitalisation • Disabling stroke • Peripheral revascularisation (cardiovascular event-free survival) For safety: combined rate of • Death, MI, disabling stroke

  6. ACTION: patient selection Stable symptomatic angina treated with: •  blockers, nitrates, etc • Lipid / blood pressure as indicated And one of the following: • History of myocardial infarction • Angiographic CAD (known abnormal angiogram, history of PTCA or CABG) • Positive exercise or radionuclide test • No history of myocardial infarction • Coronary angiography never done

  7. ACTION: exclusions • Less than 35 years of age • Clinical heart failure (HF) • EF less than 40% (2D-echo) • Valve disease • Abnormal kidney or liver function • On a CCB, digitalis for HF, class I + III anti-arrhythmic (sotalol / amiodarone allowed) • Gastrointestinal problem (absorption / passage of GITS tablet)

  8. ACTION: power calculation Sample size estimation: • Based on simvastatin arm of 4S • Assumed rate of primary endpoint for efficacy: 5.6 /100 patient-years • 30,000 patient-years planned: 80% power for 14% of primary endpoint • Exclude 3.1 excess deaths per 1000 patient-years • 37,867 patient-years realised Interim analyses to protect patient safety

  9. ACTION: design • Washout of incompatible medication • Baseline assessments • Randomised, double-blind addition of once daily Nifedipine GITS (30  60 mg) or placebo • Follow-up 4½ - 6 years • Patient contacted every three months • Out-patient clinic visit every six months

  10. 7 797allocated 5 centres (128 pts) excluded 4 didn’t start 7 665in ITT 3 825nifedipine 3 840placebo 310 died 291 died 181 incomplete 179 incomplete 3 334complete 3 370complete ACTIONtrial profile 97.3% of planned follow-up was actually completed

  11. ACTION: history and symptoms

  12. ACTION: risk factors

  13. ACTION: co-treatment at entry

  14. ACTION: tolerance % follow-up time on study medication: • 79% for nifedipine arm • 82% for placebo arm Withdrawal because of adverse event: • 10% nifedipine • 4% peripheral oedema • 1% headache • 4% placebo • 1% peripheral oedema • 0.5% headache

  15. Heart rate and blood pressure p<0.0001 p<0.0001 nifedipine placebo p<0.0001

  16. Systolic BP140, Diastolic90 mm Hg nifedipine placebo

  17. ACTION: outcome All-cause death(p=0.4) Primary endpoint for efficacy(death, MI, RA, HF, CVA, PREV)p=0.5 Primary endpoint for safety (death, MI, CVA, p=0.9) nifedipine placebo RA = refractory angina PREV = peripheral revascularisation

  18. ACTION: clinical events n=310 n=291 n=178 n=177 n=132 n=114 n=267 n=257 n=150 n=174 n=86 n=121 n=77 n=99 RR=1.07 (p=0.4) RR=1.01 (p=0.9) nifedipine placebo RR=1.16 (p=0.2) RR=1.04 (p=0.6) RR=0.86 (p=0.2) RR=0.71 (p=0.02) RR=0.78 (p=0.1)

  19. Clinical events (rates / 100 pyrs) * p<0.05

  20. Cardiovascular procedures n=895 n=1068 n=385 n=417 n=294 n=371 nifedipine placebo n=146 RR=1.25 (p=0.07) n=118 RR=0.82p<0.0001 RR=0.92 (p=0.3) RR=0.79 (p=0.002)

  21. CV procedures (rates / 100 pyrs) * p<0.05

  22. Pre-defined combined endpoints Primary endpoint for safety Cardiovascular (CV) events Primary endpoint for efficacy , any CV event or procedure Vascular events

  23. Combined endpoints n=804 n=828 n=562 n=558 n=694 n=736 n=1439 n=1583 n=1026 n=1121 1st endpoint efficacy(death, MI, RA, HF,CVA, PREV) nifedipine placebo RR=0.97(p=0.5) 1st endpoint safety(death, MI, CVA) RR=1.01 (p=0.9) CV events(CV death, MI, RA, HF,CVA, PREV) RR=0.94 (p=0.3) RR=0.89(p=0.001) Death, CV event or proc.(death, MI, RA, HF, CVA, PREV, CAG, PCI, CABG) Vascular events(CV death, MI, RA, CVA, PREV, PCI, CABG) RR=0.91 (p=0.03)

  24. Comb endp (rates / 100 pyrs)

  25. Event-free survival All-cause death (p=0.4) Death, MI, CVA(p=0.9) Death, MI, RA, HF, CVA, PREV (p=0.5) Death, CV event or proc.(death, MI, RA, HF, CVA, PREV, CAG, PCI, CABG)p=0.001 RA = refractory angina PREV = peripheral revascularisation CAG = coronary angiography PCI = percutaneous coronary interv. CABG = coronary artery bypass graft nifedipine placebo

  26. Death, any CV event or procedure First events only RR=0.89 (95% CI 0.83 – 0.95)

  27. Primary endpoint efficacy: subgroups RR, 95% CI Test for interaction: Favours nifedipine

  28. Primary endpoint efficacy: subgroups RR, 95% CI Test for interaction: Favours nifedipine

  29. ACTION: conclusions In pts with stable angina, nifedipine GITS: • overall did not prolong major cardiovascular event-free survival • is safe • prolongs cardiovascular event and procedure free survival • reduces the incidence of heart failure • prolongs major cardiovascular event-free survival in patients with angina and elevated blood pressure Manuscript is available on the Lancet Web site

  30. ACTION: conclusions In pts with stable angina, nifedipine GITS: • overall did not prolong major cardiovascular event-free survival • is safe • prolongs cardiovascular event and procedure free survival • reduces the incidence of heart failure • prolongs major cardiovascular event-free survival in patients with angina and elevated blood pressure Manuscript is available on the Lancet Web site

  31. The ACTION Research Group Steering Committee: PA Poole-Wilson (chair), H Just, M. Motro, JD Parker, MG Bourassa, AM Dart, J-M Detry(), KAA Fox, P Hildebrandt, Å Hjalmarson, JA Kragten, GP Molhoek, JE Otterstad, P Rizzon, R Seabra-Gomes, J Soler-Soler, S Weber Critical Events Committee: N Danchin (chair), A Battler, A Bayes de Luna, P Dunselman, S Glasser, P Koudstaal, G Sutton Data Monitoring / Ethical Review Committee: SJ Pocock (chair), J-P Boissel, WW Parmley, W Rutishauser, L Wilhelmsen Management: B-A Kirwan (project director), P Jonkers, J Lubsen, T Pauchard, J van Rossum, AB Parker, D Sekarski, FJ van Dalen (SOCAR Research SA) Bayer HealthCare AG: G Wagener

  32. ACTION Principal Investigators Australia – J Amerena, AM Dart, LG Howes, JA Karrasch, RW Watts.Austria - W Klein, W Lin. Belgium – C Brohet, O Gurné, G Heyndrickx, S Pourbaix, W van Mieghem, M Vrolix.Canada – P Auger, M Baird, J Bedard, G Bloomberg, M Bourassa, YK Chan, M-T Cheung, H Conter, M-A Cote, W Czarnecki, C Fortin, P Gervais, D Gossard, WKK Hui, R Iwanochko, P Klinke, WJ Kostuk, S Kouz, C Lai, A Lalani, J Lenis, S Lepage, JF Lopez, GC MacCallum, D Marr, J-P Mayer, AL Morris, M Myers, D Mymin, S Nawaz, AA Panju, JD Parker, JO Parker, P Patel, Y Pesant, SW Rabkin, M Richmond, MH Sami, M Senaratne, N Sharma, JA Stone, JH Swan, P Talbot, T Talibi, KW Tan, RM Vexler, A Walling, LCH Yao.Denmark– M Asklund, H Bjerregaard-Andersen, M Brons, F Davidsen, K Egstrup, P Eliasen, B Engby, DA Hansen, KN Hansen, P Hildebrandt, G Jensen, KK Klarlund, J Larsen, O Lederballe, H Nielsen, I Nielsen, T Nielsen, J Petersen, J Rokkedal, M Scheibel, H Sejersen, K Skagen, TV Stjernebjerg, C Torp-Pedersen. Finland – J Lilleberg, O Luurila, A Palomäki, K Peuhkurinen.France - G Amat, C Bauters, J-P Bousser, J Boutarin, P Dambrine, PP Deloy, P Gosse, P Guenoun, J-L Hirsch, E Page, C Prost, P Voiriot, S Weber. Germany – J Beermann, A Bittersohl, M Camerer, H Dill, M Frey, H-G Fritz, J Gadow, G Garanin, J Grötz, C-J Heydenreich, R Häge, J Iserloh, M Keck, HJ Kleiner, M Klutmann, S Kääb, E Lohr, G Mahla, W Motz, B Rappert, F Richard, S Schönstedt, W Sehnert, W Spitzer, B Winkelmann, J Wunderlich, U Zeymer. Greece – D Alexopoulos, N Exadaktylos, S Foussas, K Nikolaidis, P Toutouzas. Israel – EG Abinader, S Braun, A Caspi, D David, M Eldar, R Elia, M Gottsman, A Keren, Y Kishon, J Klein, BS Lewis, A Marmor, M Motro, L Reisin, T Rosenfeld, Z Schlesinger, A Weiss, I Zahavi.

  33. ACTION Principal Investigators Italy – F Arrigo, F Barillà, F Battista, L Bolognese, A Branzi, C Brunelli, C Burelli, C Chieffo, C Corona, F Crea, L Dei Cas, F Fedele, PM Fioretti, G Gensini, G Giuffrida, A Grieco, U Guiducci, P Maiolino, M Mariani, G Mattioli, F Mauri, L Meloni, P Rizzon, PJ Schwartz, D Scrutinio, P Tanzi, F Tartagni, C Vassanelli, P Zardini.New Zealand – C Ellis, H Ikram, H White. Norway – A Brandt-Rantzau, T Gundersen, HO Hoivik, H Istad, KE Langaker, S Njalla, BK Oie, TM Omland, JE Otterstad, PK Ronnevik, A Saeterhaug, PA Sirnes, SM Toft, D Torvik, K Valnes, PJ Vanberg. Portugal – V Da Gama Ribeiro, G Ferreira Da Silva, L Providencia, J Quininha, J Sa, R Seabra-Gomes, J Sieuve Afonso. Spain – J Azpitarte, JR Berrazueta, A Castro-Beiras, J-M Cruz-Fernandez, E De Los Arcos, A Fuertes, E Galve, E Gonzalez-Torrecilla, A Llamas, F Malpartida, A Martinez-Rubio, C Pagola, C Piñero, A Perez De Prado, JA Ruipérez, JR Reguero, F Sogorb, JA Velasco, JL Zamorano.Sweden – J Alvang, B Atmer, C Dahlén, G Dahlen, J Herlitz, C Höglund, S Jensen, L Karlberg, R Larsson, L Lundkvist, B Nordenhäll, P Nyman, U Ohlsson, I Timberg, J Wiberg.Switzerland – L Kappenberger, T Moccetti, B Vetter.The Netherlands – RJJ Claessens, PHJM Dunselman, BJB Hamer, DP Hertzberger, NJ Holwerda, M Kofflard, JA Kragten, GJ Laarman, CM Leenders, AH Liem, HR Michels, P Nierop, PE Polak, JL Posma, CLA Reichert, MG Scheffer, AJ Six, LC Slegers, FCW Tietge, DJ van Doorn, LHJ van Kempen, PMJ Verhorst, AJTM Vet, J Visser, FN Wempe, PHM Westendorp, AJAM Withagen.UK – PJ Allan, DI Dawson, S Dubrey, AR Fuller, RG Hardman, I Hudson, EA Leon, DP Lipkin, MB Maltz, JR Oldham, A Rozkovec, E Southall, LB Tan.

More Related